Phase I trial of the polo-like kinase (Plk) inhibitor volasertib (BI 6727) combined with cisplatin or carboplatin in patients with advanced solid tumors.
Herlinde Dumez
No relevant relationships to disclose
Andrea Gombos
No relevant relationships to disclose
Patrick Schöffski
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim
Thierry Gil
No relevant relationships to disclose
Christof Vulsteke
No relevant relationships to disclose
Marie-Anne Meeus
Employment or Leadership Position - Boehringer Ingelheim
Jessica Cescutti
Employment or Leadership Position - Boehringer Ingelheim
Gerd Michael Munzert
Employment or Leadership Position - Boehringer Ingelheim
Korinna Pilz
Employment or Leadership Position - Boehringer Ingelheim
Ahmad Awada
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Boehringer Ingelheim